Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Autor: | Machado RB; a Department of Gynaecology and Obstetrics , Jundiaí School of Medicine , Jundiaí , Brazil., Pompei LM; b Department of Gynaecology and Obstetrics , ABC School of Medicine , Santo André , Brazil., Badalotti M; c Department of Gynaecology and Obstetrics , PUC-RS, Porto Alegre , Brazil., Ferriani R; d Department of Gynaecology and Obstetrics , University of São Paulo (FMRP-USP) , Ribeirão Preto , Brazil., Cruz AM; e Department of Clinical Research , Libbs Farmacêutica Ltda , São Paulo , Brazil., Nahas E; f Department of Gynaecology and Obstetrics , Botucatu School of Medicine (FMB-UNESP), UNESP - Sao Paulo State University , Botucatu , Brazil., Maia H Jr; g Centre for Research and Assistance in Human Reproduction , Federal University of Bahia , Salvador , Brazil. |
---|---|
Jazyk: | angličtina |
Zdroj: | The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception [Eur J Contracept Reprod Health Care] 2017 Feb; Vol. 22 (1), pp. 11-16. Date of Electronic Publication: 2016 Sep 29. |
DOI: | 10.1080/13625187.2016.1239077 |
Abstrakt: | Objectives: The aim of the study was to assess the efficacy for menstrual-related symptoms of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone in comparison with a 24/4 d cyclical regimen of the same formulation. Methods: This randomised, non-inferiority, open-label, multicentre study was conducted in women aged 18-39 years. Their menstrual-related symptoms were assessed using the Penn Daily Symptom Rating (DSR17). Participants were randomised to use an extended flexible regimen of 20 μg ethinylestradiol and 3 mg drospirenone (EE/DRSP Results: The primary analysis demonstrated that EE/DRSP Conclusion: The extended flexible regimen was not inferior to the 24/4 cyclical regimen in terms of the primary endpoint. It significantly improved symptoms in the interval analysis, and the effects on specific DSR17 symptoms, compared with the cyclical regimen. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |